|
|
| | DHODH-IN-25 Basic information |
| Product Name: | DHODH-IN-25 | | Synonyms: | DHODH-IN-25;1-Pyrrolidinecarboxamide, N-[4-[[(2-chloro-6-fluorophenyl)amino]carbonyl]-2-fluoro-5-[(1S)-2,2,2-trifluoro-1-methylethoxy]phenyl]-2-(hydroxymethyl)-5-oxo- | | CAS: | 2619531-95-0 | | MF: | C22H19ClF5N3O5 | | MW: | 535.85 | | EINECS: | | | Product Categories: | | | Mol File: | 2619531-95-0.mol |  |
| | DHODH-IN-25 Chemical Properties |
| density | 1.546±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 9.59±0.70(predicted) |
| | DHODH-IN-25 Usage And Synthesis |
| Uses | DHODH-IN-25 (Compound 25) is an orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 value of 5.4 nM for human DHODH. DHODH-IN-25 can be used for the study of acute myeloid leukemia (AML)[1]. | | References | [1] DeRatt, Lindsey G., et al. "Discovery of Alternative Binding Poses through Fragment-Based Identification of DHODH Inhibitors." ACS Medicinal Chemistry Letters (2024). |
| | DHODH-IN-25 Preparation Products And Raw materials |
|